Showing 4,641 - 4,660 results of 43,928 for search '(( 5 ((we decrease) OR (nn decrease)) ) OR ( 50 ((ns decrease) OR (mean decrease)) ))', query time: 0.71s Refine Results
  1. 4641

    Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms by Farman M. Abbasi (22318766)

    Published 2025
    “…Current treatments, such as teriparatide, boost bone formation but also elevate resorption, limiting their long-term effectiveness. We discovered 3-butyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-<i>d</i>]pyrimidin-4(3<i>H</i>)-one <b>(5cc)</b>, an orally active phosphodiesterase-1 (PDE1) inhibitor aimed at restoring this balance. …”
  2. 4642

    Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms by Farman M. Abbasi (22318766)

    Published 2025
    “…Current treatments, such as teriparatide, boost bone formation but also elevate resorption, limiting their long-term effectiveness. We discovered 3-butyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-<i>d</i>]pyrimidin-4(3<i>H</i>)-one <b>(5cc)</b>, an orally active phosphodiesterase-1 (PDE1) inhibitor aimed at restoring this balance. …”
  3. 4643

    Initial treatment regimen. by Shivani Patel (4742748)

    Published 2024
    “…We reviewed the charts of adult patients diagnosed with locally advanced or metastatic BCC treated with vismodegib or sonidegib primarily for progression-free survival (PFS). …”
  4. 4644

    Patients baseline characteristics. by Shivani Patel (4742748)

    Published 2024
    “…We reviewed the charts of adult patients diagnosed with locally advanced or metastatic BCC treated with vismodegib or sonidegib primarily for progression-free survival (PFS). …”
  5. 4645

    Charge-Transfer-Driven Electrical Conductivity in Single Crystals of Assembled Triphenylamine Bis-urea Macrocycles by Fahidat A. Gbadamosi (22123930)

    Published 2025
    “…By encapsulating guests with varying reduction potentials, including 2,5-dichloro-1,4-benzoquinone (ClBQ), 2,1,3-benzothiadiazole (BTD), and malononitrile (MN), we observed significant changes in the electrical conductivity. …”
  6. 4646

    Charge-Transfer-Driven Electrical Conductivity in Single Crystals of Assembled Triphenylamine Bis-urea Macrocycles by Fahidat A. Gbadamosi (22123930)

    Published 2025
    “…By encapsulating guests with varying reduction potentials, including 2,5-dichloro-1,4-benzoquinone (ClBQ), 2,1,3-benzothiadiazole (BTD), and malononitrile (MN), we observed significant changes in the electrical conductivity. …”
  7. 4647

    Charge-Transfer-Driven Electrical Conductivity in Single Crystals of Assembled Triphenylamine Bis-urea Macrocycles by Fahidat A. Gbadamosi (22123930)

    Published 2025
    “…By encapsulating guests with varying reduction potentials, including 2,5-dichloro-1,4-benzoquinone (ClBQ), 2,1,3-benzothiadiazole (BTD), and malononitrile (MN), we observed significant changes in the electrical conductivity. …”
  8. 4648

    Overall survival. by Shivani Patel (4742748)

    Published 2024
    “…We reviewed the charts of adult patients diagnosed with locally advanced or metastatic BCC treated with vismodegib or sonidegib primarily for progression-free survival (PFS). …”
  9. 4649

    Charge-Transfer-Driven Electrical Conductivity in Single Crystals of Assembled Triphenylamine Bis-urea Macrocycles by Fahidat A. Gbadamosi (22123930)

    Published 2025
    “…By encapsulating guests with varying reduction potentials, including 2,5-dichloro-1,4-benzoquinone (ClBQ), 2,1,3-benzothiadiazole (BTD), and malononitrile (MN), we observed significant changes in the electrical conductivity. …”
  10. 4650

    CHWs house visits. by Nicole Michelén Ströfer (19269154)

    Published 2024
    “…The performance of the malaria CHW network was evaluated using weekly data collected from CHWs and routinely collected surveillance data from the Ministry of Public Health (MoH). We assess performance of CHWs by analyzing key variables including (1) reporting compliance, (2) household visitation rates, (3) malaria rapid diagnostic tests performed, (4) malaria cases detected, and (5) time between symptom onset and malaria diagnosis. …”
  11. 4651

    Progression-free survival by treatment. by Shivani Patel (4742748)

    Published 2024
    “…We reviewed the charts of adult patients diagnosed with locally advanced or metastatic BCC treated with vismodegib or sonidegib primarily for progression-free survival (PFS). …”
  12. 4652

    Charge-Transfer-Driven Electrical Conductivity in Single Crystals of Assembled Triphenylamine Bis-urea Macrocycles by Fahidat A. Gbadamosi (22123930)

    Published 2025
    “…By encapsulating guests with varying reduction potentials, including 2,5-dichloro-1,4-benzoquinone (ClBQ), 2,1,3-benzothiadiazole (BTD), and malononitrile (MN), we observed significant changes in the electrical conductivity. …”
  13. 4653

    Maintenance regimen and adverse event management. by Shivani Patel (4742748)

    Published 2024
    “…We reviewed the charts of adult patients diagnosed with locally advanced or metastatic BCC treated with vismodegib or sonidegib primarily for progression-free survival (PFS). …”
  14. 4654

    Charge-Transfer-Driven Electrical Conductivity in Single Crystals of Assembled Triphenylamine Bis-urea Macrocycles by Fahidat A. Gbadamosi (22123930)

    Published 2025
    “…By encapsulating guests with varying reduction potentials, including 2,5-dichloro-1,4-benzoquinone (ClBQ), 2,1,3-benzothiadiazole (BTD), and malononitrile (MN), we observed significant changes in the electrical conductivity. …”
  15. 4655

    BCC-specific survival. by Shivani Patel (4742748)

    Published 2024
    “…We reviewed the charts of adult patients diagnosed with locally advanced or metastatic BCC treated with vismodegib or sonidegib primarily for progression-free survival (PFS). …”
  16. 4656

    Optical coherence tomography findings. by Eisuke Usui (12111855)

    Published 2024
    “…After PCI, hDPV significantly increased from 55.6 cm/s to 69.5 cm/s (P<0.01), with a median %hDPV increase of 27.2 (6.32–59.1) %, while %hDPV decreased in 20 (19.4%) patients. …”
  17. 4657

    S1 Data - by Eisuke Usui (12111855)

    Published 2024
    “…After PCI, hDPV significantly increased from 55.6 cm/s to 69.5 cm/s (P<0.01), with a median %hDPV increase of 27.2 (6.32–59.1) %, while %hDPV decreased in 20 (19.4%) patients. …”
  18. 4658

    Clinical demographics and angiographic findings. by Eisuke Usui (12111855)

    Published 2024
    “…After PCI, hDPV significantly increased from 55.6 cm/s to 69.5 cm/s (P<0.01), with a median %hDPV increase of 27.2 (6.32–59.1) %, while %hDPV decreased in 20 (19.4%) patients. …”
  19. 4659

    Physiological parameters. by Eisuke Usui (12111855)

    Published 2024
    “…After PCI, hDPV significantly increased from 55.6 cm/s to 69.5 cm/s (P<0.01), with a median %hDPV increase of 27.2 (6.32–59.1) %, while %hDPV decreased in 20 (19.4%) patients. …”
  20. 4660